ARK Genomic Revolution ETF vs Vanguard Short Term Corporate Bond ETF — how do they compare? ARK Genomic Revolution ETF trades at $44.46, while Vanguard Short Term Corporate Bond ETF trades at $78.58. The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | VCSH | |
|---|---|---|
Sector | Sector/Thematic | Fixed Income |
52-Week High | $44.55 | $80.20 |
52-Week Low | $24.02 | $78.41 |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VCSH trades at $78.59 with minimal daily movement (+0.13%). Technical indicators show a bearish trend with all moving averages signaling sell, though oscillators remain neutral. The ETF maintains a 4.8% yield but faces headwinds from tight credit spreads and an unattractive entry point according to recent analysis. Recent institutional activity shows mixed sentiment with both position increases and decreases.
The outlook remains cautious with limited upside potential due to current rate environment and credit spread compression. Key risks include interest rate sensitivity and competitive pressure from treasury-focused alternatives. Investors seeking short-term corporate bond exposure should monitor credit quality and duration management.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →